Clinical observation of Conbercept in the treatment of patients with wet age-related macular degeneration
Author:
  • Article
  • | |
  • Metrics
  • |
  • Reference [20]
  • |
  • Related
  • | | |
  • Comments
    Abstract:

    AIM: To observe the clinical characteristics and influence factors of different responses in patients with wet age-related macular degeneration(wARMD)treated with intravitreal conbercept.

    METHODS: A total of 62 eyes(56 patients)with wet age-related macular degeneration who received intravitreal Conbercept injections(3+PRN)in our hospital from January to September 2018 were retrospectively analyzed. The best-corrected visual acuity(BCVA)and optical coherence tomography(OCT)were performed before and after treatment. Responses were evaluated and grouped according to BCVA after the last injection. 33 cases of 35 eyes with BCVA improvement ≥5 letters were included in the response group. 23 cases with 27 eyes were included in the non-response group. Before and after treatment, BCVA, central retinal thickness(CRT)and related data of the two groups were analyzed.

    RESULTS: One month after 3 injections, BCVA in the response group increased from 41.83±7.92 letters at baseline to 52.52±10.61 letters(t= -6.883, P=0.02), and BCVA increased from 43.65 ± 10.42 letters at baseline to 44.18 ± 8.47 letters in the non-response group(t=0.471, P=0.684).CRT of the two groups after treatment decreased from the baseline(F=31.47, 27.28, all P<0.01). Six months after 3 injections, the proportion of patients with the integrity of the macular fovea ellipsoid in response group(69%)was more than that in the non-responsive group(7%), and the proportion of patients with subretinal fluid(86%)was higher than that without SRF in the response group(44%), the proportion of patients with intraretinal fluid(31%)in the response group was lower than that in the non-response group(81%)(all P<0.05), but there was no difference in the proportion of patients with pigment epithelial detachment between the two groups(77% vs 59%, P> 0.05).

    CONCLUSION: Intravitreal injections of conbercept can effectively reduce the subretinal fluid and retinal fluid in patients with wet age-related macular degeneration, and improve the patient's visual acuity. Patients with the integrity of the outer layer of the retina(especially the ellipsoidal zone)and SRF responded well after treatment, while patients with IRF responded poorly after treatment.

    Reference
    1 Ong BB, Ah-Fat FG. Age-related maculardegeneration. Br J Hosp Med(Lond) 2016; 77(2): C18-21
    2 Holz FG, Tadayoni R, Beatty S, et al. Key drivers of visual acuity gainsin neovascular age-related macular degeneration in real life: findingsfrom the AURA study. Br J Ophthalmol 2016; 100(12): 1623-1628
    3 Lai K, Landa G. Current choice of treatments for neovascular AMD. Expert Rev Clin Pharmacol 2015; 8(1): 135-140
    4 Zhang J, Liang Y, Xie J, et al. Conbercept for patients with age-related macular degeneration: a systematic review. BMC Ophthalmol 2018; 18(1): 142
    5 Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-relatedmacular degeneration by the European Society of Retina Specialists(EURETINA). Br J Ophthalmol 2014; 98(9):1144-1167
    6 American academy of ophthalmology. Age-Related Macular Degeneration PPP-Updated 2015. https://www.aao.org/preferred-practicepattern/age-related-macular-degeneration-ppp-2015
    7 Zhang M, Yu D, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 2009; 26(1):204-210
    8 Lu X, Sun X. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther 2015; 9:2311-2320
    9 Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitrealaflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014; 121(1):193-201
    10 Li X, Xu G, Wang Y, et al. Safety and efficacy ofConbercept in neovascular age-related macular degeneration: results from a 12-month randomizedphase 2 study: AURORA study. Ophthalmology 2014; 121(9):1740-1747
    11 Liu K, Song YP, Xu GZ.Conbercept for Treatment of Neovascular Age-related Macular Degeneration:Results of the Randomized Phase 3 PHOENIX study. Am J Ophthalmol 2019; 197: 156-167
    12 Curcio CA, Sparrow JR, Bonilha VL, et al. Cellular characterization of OCT and outer retinal bands using specific immunohistochemistry markers and clinical implications. Ophthalmology 2018; 125(7): e47-e48
    13付浴东, 孟旭霞, 王萍, 等. 不同光相干断层扫描分型糖尿病黄斑水肿玻璃体腔注射雷珠单抗的疗效差异及患眼椭圆体带完整性与视力的相关性. 中华眼底病杂志 2017; 33(2): 129-133
    14 Ota M, Tsujikawa A, Murakami T, et al. Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion. Br J Ophthalmol 2007; 91(12): 1644-1649
    15 Ashraf M, Souka A, Adelman R. Predicting outcomes to antivascular endothelial growth factor(VEGF)therapy in diabetic macular oedema: a review of the literature. Br J Ophthalmol 2016; 100:1596-1604
    16 Waldstein SM, Simader C, Staurenghi G, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology 2016; 123(7):1521-1529
    17 Schmidt-Erfurth U, Waldstein SM, Deak GG, et al. Pigment Epithelial Detachment Followed by Retinal Cystoid Degeneration Leads to Vision Loss in Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmology 2015; 122(4):822-832
    18 Jaffe GJ, Martin DF, Toth CA, et al. Macular morphology andvisual acuity in the comparison of age-related macular degenerationtreatments trials. Ophthalmology 2013; 120(9):1860-1870
    19 Li X, Luo H, Zuo C, et al. Conbercept in patients with treatment-naive neovascular age-related macular degeneration in real-life setting in China. Retina 2019; 39(7): 1353-1360
    20黄定国,岑令平,张安琳, 等. 频域光学相干断层扫描观察康柏西普治疗老年性黄斑变性患者黄斑结构的变化. 眼科新进展2018; 38(12):1157-1160
    Related
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Si Zhang, Qing Li, Hui Chen. ,/et al.Clinical observation of Conbercept in the treatment of patients with wet age-related macular degeneration. Guoji Yanke Zazhi( Int Eye Sci) 2020;20(5):787-790

Copy
Share
Article Metrics
  • Abstract:908
  • PDF: 1168
  • HTML: 0
  • Cited by: 0
Publication History
  • Received:November 05,2019
  • Revised:April 15,2020
  • Online: April 26,2020